BioPlus Acquisition Corp.
BIOSU
NASDAQ Global Market10.80
USD
-0.04
- -
CIK
0001856653
CUSIP
G11217109
Return %
Stock
S&P500
1Y
6.30
26.84
3Y
7.89
77.03
5Y
7.89
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- R. Ross Haghighat
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 260 Madison Avenue New York City NY United States of America 10026
- IPO Date
- Dec 3, 2021
- CIK
- 0001856653
- Website
- bioplusspac.com
- Similar Companies
- Business
- BioPlus Acquisition Corp. (NASDAQ:Biosu) is a blank check company whose principal business activity is to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It focuses on target companies in the life sciences and healthcare industries, particularly across the United States, European Union, Israel and Australasia; it offers no other products or services. BioPlus Acquisition Corp. was incorporated in 2021 and is headquartered in New York, New York. In October 2023, the company mutually terminated its definitive business combination agreement, dated May 2023, with Avertix Medical Inc., a developer of implantable cardiac monitoring devices, and announced its intention to liquidate and return funds to public shareholders as soon as practicable thereafter, with shareholders receiving approximately $10.79 per share upon redemption; its sponsor waived redemption rights, and outstanding warrants expired worthless. The company has not pursued or announced any subsequent business combinations, acquisitions, partnerships or strategic shifts since the termination and remains in the process of winding down operations without generating revenue or commencing substantive business activities.